Skip to main content

Blackman Samuel C.'s Form 4 filing

Day One Biopharmaceuticals, Inc. (DAWN) · filed Feb 20, 2024

Accession no.
0001415889-24-004459
Filed
Feb 20, 2024
Trade date
Feb 15-16, 2024
Filing delay
5 days
Rule 10b5-1 plan
Not checked

This filing lists 4 non-derivative transactions and 3 derivative transactions. Open-market sales total $34.4K. It was filed 5 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Blackman Samuel C.CIK 0001863676Officer (HEAD OF RESEARCH AND DEVELOPME)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Feb 15, 2024Common StockMOption exerciseAcquired+1,187–F1–1,239,421Direct
Feb 15, 2024Common StockMOption exerciseAcquired+1,437–F1–1,240,858Direct
Feb 15, 2024Common StockMOption exerciseAcquired+6,062–F1–1,246,920Direct
Feb 16, 2024Common StockSSaleDisposed−2,258$15.25−$34,434.51,244,662Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Feb 15, 2024Common StockMOption exerciseDisposed−1,187$0.00$08,317Direct
Feb 15, 2024Common StockMOption exerciseDisposed−1,437$0.00$015,815Direct
Feb 15, 2024Common StockMOption exerciseDisposed−6,062$0.00$090,938Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration.

Referenced by the price of 3 transactions in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)